Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia

You'll see patients getting Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia.

Aranesp is approved for anemia associated with chronic renal failure...including patients not yet on dialysis.

It's also being studied for anemia due to cancer chemotherapy.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote